Epioxa crosslinking system has positive outcomes at 30 months in patients with keratoconus
Kenneth Beckman, MD, of Columbus Eye Surgery Center, spoke with Ophthalmology 360 at the 2026 ASCRS Annual Meeting about his study that found that at 30 months, treatment with Epioxa continued to be effective.
Kenneth Beckman, MD:
Hi, I’m Ken Beckman. I’m a corneal specialist from Columbus, Ohio. I’d like to talk today about the Epioxa crosslinking system, which has been developed by Glaukos. Epioxa is used for epithelium on crosslinking and was just approved last fall. I was fortunate enough to be part of both of the pivotal FDA trials for approval. Just to briefly summarize what we found in these trials, they looked at a treatment arm and a sham arm, two-thirds of the patients got treatment and one-third got the sham. They looked at the difference in Kmax between the 2 arms. The first study, the endpoint was at 6 months, the second study was at 12 months. In each study, there was greater than 1.0 diopters of difference in Kmax between the treatment arm and the sham arm, which is an excellent result, and that led to the approval. But, we all have questions about the long-term efficacy of these medications and what happens later.
The first study where the primary improvement was 6 months, these patients were followed out to 36 months. I just recently presented the 30-month data at ASCRS. At 30 months, what we found was the treatment arm actually continued to flatten by a total of 1.74 diopters from baseline. That’s not the delta between the 2 arms, that’s just how much flattening that arm showed. The important thing that we find here is not only did we have continued response without a rebound, but we found continued flattening. This is really exciting and it shows that with Epioxa treatment, you can get a significant successful treatment that continues to work for months afterwards. Thank you.
Related Content
